Results 21 to 30 of about 252,541 (298)
A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors [PDF]
Journal of Translational Medicine, 2013 Chimeric Antigen Receptors (CARs) consist of the antigen-recognition portion of a monoclonal antibody fused to an intracellular signaling domain capable of activating T-cells. CARs displayed on the surface of transduced cells perform non-MHC-restricted antigen recognition and activating intracellular signaling pathways for induction of target cytolysis,
De Oliveira, SN +5 more
openaire +6 more sources
Viral Delivery of CAR Targets to Solid Tumors Enables Effective Cell Therapy
Molecular Therapy: Oncolytics, 2020 Chimeric antigen receptor (CAR) T cell therapy has had limited efficacy for solid tumors, largely due to a lack of selectively and highly expressed surface antigens.
Amin Aalipour +8 more
doaj +1 more source
Efficacy of Dual Cd19-Cd79B Car In B-Cell Malignancies [PDF]
, 2022 Despite high clinical responses, about 30%-60% of patients with B-cell malignancies relapse following CD19-targeting chimeric antigen receptor (CAR) T cell therapy. CD19 loss is a major cause of relapse and resistance after CD19 CAR T therapy.
Cheng, Xiaoyun
core +1 more source
TriBAFF-CAR-T cells eliminate B-cell malignancies with BAFFR-expression and CD19 antigen loss
Cancer Cell International, 2021 Background To investigate the effect of TriBAFF-CAR-T cells on hematological tumor cells. Methods TriBAFF-CAR-T and CD19-CAR-T cells were co-cultured with BAFFR-bearing B-cell malignancies at different effector/target ratios to evaluate the anti-tumor ...
Guangchao Li +11 more
doaj +1 more source
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies [PDF]
Journal of Clinical Investigation, 2016 Potent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART) and blinatumomab, have drastically changed the outcome of patients with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). However, CD19-negative relapses have emerged as a major problem that is observed in approximately 30% of treated patients ...
Marco Ruella +20 more
openaire +2 more sources
International Journal of Nanomedicine, 2023 CAR-T cell therapy is effective in the treatment of certain hematological malignancies, and the expansion and functional persistence of CAR-T cells in vivo are crucial to clinical efficacy. The aim of this study was to investigate the potential of extracellular vesicles (EVs) modified with the CAR antigen to promote the efficacy of CAR-T cells in vivo ...
Yuanyuan Zhang +10 more
openaire +4 more sources
Hematology, Transfusion and Cell Therapy, 2023 Introduction: The recent active use of immunotherapy based on CD19/CD3 bispecific T-cell engager (blinatumomab), brings significant problems on monitoring Minimal Residual Disease (MRD) based on Multiparameter Flow Cytometry (MFC), due to possible CD19 ...
RM Pontes +9 more
doaj +1 more source
Rejection of Experimental Hodgkins Lymphoma by T-cells Engineered with a CD19 Chimeric Antigen Receptor [PDF]
, 2012 T cells engineered to express chimeric receptors combining an external antibody binding domain with the CD3ζ T cell receptor (TCR) internal domain for triggering cell activation are being used for immunotherapeutic targeting of tumour cells in a non-HLA ...
Cheadle, Eleanor +8 more
core +1 more source
Cells, 2022 Given the importance of B lymphocytes in inflammation and immune defense against pathogens, mice transgenic for Cre under the control of Cd19 promoter (Cd19Cre/+ mice) have been widely used to specifically investigate the role of loxP-flanked genes in B ...
Ying Zhao +9 more
doaj +1 more source
, 2021 CD19-directed treatment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) frequently leads to the downmodulation of targeted antigens. As multicolour flow cytometry (MFC) application for minimal/measurable residual disease (MRD) assessment in ...
Semchenkova A. +21 more
core +1 more source